Company intelligence / Profile preview
Beijing Kecellitics Biotech Co., Ltd.
Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple CAR-T cell therapies in development, with their dual-targeting CD19 and CD22 CAR-T cell therapy reaching Phase 2 clinical trials for B-Cell Lymphoma. Their Anti-CD19-CAR T cell therapy is in Phase 1 for B-Cell Leukemia with a 71% phase transition success rate for progressing into Phase 2. Their Anti-CD22-CAR T cell therapy has reached Phase 2 for multiple indications including Acute Lymphoblastic Leukemia, B-Cell Lymphoma, B-Cell Malignant Neoplasm, and Chronic Lymphocytic Leukemia.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapiesAutologous CAR-T
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Beijing Kecellitics Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Kecellitics Biotech Co., Ltd..